Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED90 of esketamine with flurbiprofen for movement suppression in ambulatory hysteroscopy
ChiCTR2400080615Phase 4Not yet recruiting
- Sponsor
- Hainan General Hospital
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of esketamine in endometrial polyp, sponsored by Hainan General Hospital. Primary endpoint: ED90 of esketamine for suppression of body movement. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
endometrial polyp
Beyond the preview
Go deeper on ChiCTR2400080615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080615.